-
FDA Approves Companion Diagnostic for T-DXd in HER2-Ultralow Metastatic Breast Cancer
03 Feb 2025 19:35 GMT
… 1 “The rising incidence of metastatic breast cancer, particularly among younger populations, … patients with HER2-ultralow metastatic breast cancer eligible for Enhertu. News … -low or HER2-ultralow metastatic breast cancer following disease progression after …
-
FDA Approval Expands Earlier Use of Enhertu for Metastatic Breast Cancer
03 Feb 2025 18:59 GMT
… or HER2-ultralow breast cancer.
The approval was … or HER2-ultralow metastatic breast cancer. Patients randomly assigned … with HER2-expressing metastatic breast cancer," Dave Fredrickson … importance of testing metastatic breast cancer tumors for detectable …
-
FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer
03 Feb 2025 19:35 GMT
… with HER2-positive breast cancer.1
Pertuzumab is … with HER2-positive metastatic breast cancer who have not … inflammatory breast cancer; had stage IV, bilateral, or multicentric breast cancer; … stage or locally advanced breast cancer. ClinicalTrials.gov. …
-
A Road Map for Change Report Provides a Guide to Elevate Breast Cancer Care
03 Feb 2025 19:35 GMT
… individuals living with metastatic breast cancer who have … Breast Cancer Symposium [SABCS] and the Miami Breast Cancer … Hidden Costs of Breast Cancer
Breast cancer incidence rates … al; Lancet Breast Cancer Commission. The Lancet Breast Cancer Commission. …
-
Breakthrough: Houston Methodist Researchers Discover Inhibitor Drugs for Targeting Aggressive Breast Cancer
03 Feb 2025 14:14 GMT
… of metaplastic breast cancer, a … -negative breast cancer have … breast cancer
Article Title: NOS inhibition sensitizes metaplastic breast cancer … breast cancer inhibitorscancer metastasis researchHouston Methodist research breakthroughmetaplastic breast cancer …
-
Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy
03 Feb 2025 12:15 GMT
… of highly malignant breast cancers, including TNBC, … K, Yoon H. Breast cancer metastasis: mechanisms and therapeutic implications … nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics. … therapy treatment of breast tumours using ultrasound …
-
Daiichi Sankyo & AstraZeneca's datopotamab deruxtecan recommended for approval in EU to treat patients with previously treated metastatic HR positive, HER2 negative breast cancer
03 Feb 2025 10:20 GMT
… , HER2 negative metastatic breast cancer as assessed by … treatment for metastatic HR positive breast cancer. However, … unresectable or recurrent breast cancer after prior chemotherapy … negative breast cancer and HR positive, HER2 negative breast cancer. …
-
US FDA approves label expansion for Roche's Pathway HER2 (4B5) test to identify patients with HER2─ultralow metastatic breast cancer eligible for Enhertu
03 Feb 2025 04:43 GMT
… HR-positive, HER2-ultralow metastatic breast cancer who may be eligible for … . “The rising incidence of metastatic breast cancer, particularly among younger populations, … HER2-low and HER2-ultralow metastatic breast cancer. An exploratory analysis showed …
-
More cancer diagnoses again last year; Prostate cancer almost as common as breast cancer
03 Feb 2025 07:34 GMT
… now almost as common as breast cancer, the Comprehensive Cancer Center … growth and aging population. Breast cancer is the most common form … more likely to already have metastatic cancer at the time … of women dying of breast cancer has been slowly declining …
-
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™
03 Feb 2025 12:30 GMT
Lung metastasis (from metastatic breast cancer) … immunotherapy in metastatic breast cancer
PHILADELPHIA and … metastatic breast cancer. Key inclusion criteria include recurrent metastatic breast cancer … inhibitor in metastatic breast cancer. Forward-looking …